Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 3/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 12/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | CRAT | P43155 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4760783 | 0.96 | PLA2G2C (0.42) | PLA2G2CENPEPCA12CA1CA2 | |
| SCHEMBL11695028 | 0.81 | TGFBR1 (0.42) | PLA2G2CENPEPCA12CA1CA2 | |
| SCHEMBL4760781 | 0.80 | PLA2G2C (0.41) | PLA2G2CENPEPCA12CA1CA2 | |
| SCHEMBL6570577 | 0.80 | PLA2G2C (0.41) | PLA2G2CENPEPCA12CA1CA2 | |
| SCHEMBL28057523 | 0.79 | CA12 (0.41) | PLA2G2CCA12CA1CA2MMP1 | |
| SCHEMBL3957758 | 0.77 | PLA2G2C (0.37) | PLA2G2CENPEPCRAT | |
| SCHEMBL9752421 | 0.77 | TSHR (0.41) | ENPEPCA12CA1CA2MMP1 | |
| SCHEMBL6569603 | 0.77 | ENPEP (0.36) | PLA2G2CENPEPACACB | |
| SCHEMBL8367402 | 0.76 | TAS1R3 (0.46) | PLA2G2CCA12CA1CA2MMP1 | |
| SCHEMBL3953473 | 0.75 | PLA2G2C (0.35) | PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1056445-B1 | ORALLY ADMINISTRABLE IMMEDIATE-RELEASE AND PROLONGED-RELEASE GALENIC FORM COMPRISING AN ABSORPTION-PROMOTING AGENT AND USE OF THIS ABSORPTION-PROMOTING AGENT | MERCK PATENT GMBH (DE) | 2004-06-02 | — | — | EP | disclosed |
| EP-1410791-A1 | Orally administrable galenic form comprising metformine and an absorption-promoting agent | MERCK PATENT GmbH (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-6514524-B1 | Improved absorption of hydrophilic ingredients because of particular excipients; calcium 3-acetylamino-1-propane sulfonate (calcium acamprosate); polysorbates, fatty ethers or esters of PEG, polyglycolysed glycerides | MERCK PATENTGESELLSCHAFT MIT (DE) | 2003-02-04 | — | — | US | disclosed |
| US-6426087-B1 | GALENIC FORMS; SUSTAINED RELEASE | MERCK PATENT GESELLSCHAFT MIT (DE) | 2002-07-30 | — | — | US | disclosed |